Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

TitleDifferential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Publication TypeJournal Article
Year of Publication2009
AuthorsFeusner, JD, Kerwin L, Saxena S, Bystritsky A
JournalPsychopharmacology bulletin
Volume42
Issue1
Pagination81-93
Date Published2009
ISSN0048-5764
KeywordsAdult, Anxiety Disorders, Excitatory Amino Acid Antagonists, Female, Humans, Male, Memantine, Middle Aged, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Young Adult
Abstract

A substantial proportion of patients with obsessive-compulsive disorder (OCD) and generalized anxiety disorder (GAD) do not respond to, or are intolerant of, standard treatments. Additional treatment strategies are therefore necessary. Excessive action of the excitatory neurotransmitter glutamate may play a role in the pathophysiology of OCD and possibly GAD. Memantine blocks the excitatory action of glutamate at the N-methyl- D-aspartate (NMDA) receptor under pathological conditions. The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms.

Alternate JournalPsychopharmacol Bull